CD10+ stromal cells form B-lymphocyte maturation niches in the human bone marrow

In adult mammals, early B-lymphopoiesis takes place in the bone marrow in close association with stromal cells. Both the phenotype of the stromal cells and the molecules involved in this essential interaction are as yet inadequately described. In this study, all benign, differentiating B-cells (Pax-5+ lymphoid cells) are shown, by using two-colour immunohistochemistry on biopsies from human bone marrow, to be in close contact with scant dendritic CD10+ stromal cells until they leave via the sinusoids. This CD10+ stromal cell population does not fully overlap with the VCAM-1+ stromal cell population. Furthermore, using a set of B-cell differentiation markers (TdT, Pax-5, and CD20), B-cell development is shown to be spatially oriented, with maturation progressing towards bone marrow sinusoids. In conclusion, CD10+ stromal cells form distinct B-lymphocyte maturation niches in the human bone marrow.     

Human bone marrow contains a subset of quiescent early memory CD8+ T cells characterized by high CD127 expression and efflux capacity

Even today it is still not completely understood how CD8⁺ T‐cell memory is maintained long term. Since bone marrow (BM) is a niche for immunological memory, we sought to identify long‐lasting early memory CD8⁺ T cells in this compartment. To achieve this, we looked for CD8⁺ T cells that are able to efflux Rhodamine 123, a typical property of stem cells. Indeed, we identified a distinct subset of CD8⁺ T cells in BM, with the capacity to efflux and high CD127 expression. These CD127^hi effluxers are conventional CD8⁺ T cells exhibiting a broad TCR‐Vβ repertoire and are generated in response to viral peptides in vitro. CD127^hi effluxer CD8⁺ T cells have an early memory phenotype defined by preferential TNF‐α production and a Bcl‐2^hi, KLRG‐1^low profile. This population has long telomeres and shows constitutively low frequencies of Ki‐67 expression ex vivo, but has a high proliferative and differentiation capacity in vitro. However, IL‐15 downmodulates CD127 in CD127^hi effluxer CD8⁺ T cells in vitro. Consequently, the CD127^low effluxer subset may comprise cells recently exposed to IL‐15. Taken together, CD127^hi effluxer CD8⁺ T cells represent a novel population of early memory T cells resident in BM with properties required for long‐lived memory.     

Characterization of porcine CD5 and CD5+ B cells

Evidence strongly supports a role for the lymphocyte transmembrane glycoprotein CD5 in intracellular signalling events, whereby antigen-dependent growth and differentiation signals are augmented. Apart from its role in activation-related signalling, CD5 has been regarded as a possible B cell lineage marker differentiating subsets, CD5⁺ B cells (also termed B1 cells) and conventional B cells (or B2 cells). To extend these investigations to the study of pigs, porcine B cells were examined for evidence of CD5 expression. The influence of cellular activation on CD5 expression and CD5's role in signal transduction events and lymphocyte proliferation were examined. Using an anti-porcine CD5 MoAb (b53b7), porcine B cells were shown to be heterogeneous for CD5 expression. As in other species, B lymphocyte CD5 expression is low (dull), while IgM is high (bright). Ten to 30% of pig blood B lymphocytes are CD5⁺, with the highest frequency in neonates. Anti-CD5 antibody treatment was sufficient to induce rapid but transient calcium ion flux in porcine peripheral blood lymphocytes (PBL). CD5 expression increased on PBL following treatment with phorbol myristate acetate (PMA), lipopolysaccharide (LPS), or immobilized anti-IgM. LPS, PMA, and concanavalin A (Con A) but not anti-CD5, anti-IgM, or combinations of these antibodies induced lymphocyte ³H-thymidine uptake. CD5⁺ B cells are a common constituent of porcine circulating lymphocytes and resemble B1 cells of mice, man and other species in CD5 expression, frequency and lymphoid organ distribution. Porcine CD5, like CD5 in other species, mediates signal transduction, leading to changes in intracellular calcium concentration, but this signal alone is insufficient to promote cell division. A subset of porcine B cells up-regulates CD5 expression following phorbol ester activation.     

Expression of CD5 and CD38 by human CD5− B cells: Requirement for special stimuli

In this study the mode of expression of CD5 by human tonsillar CD5^? B cells after stimulation with different agents was investigated. Resting B cells were separated into CD5⁺ and CD5^? cells and the two cell fractions exposed to phorbol 12-myristate 13-acetate (PMA). CD5^? B cells expressed CD5 and maximum CD5 expression was achieved after approximately 60 h of culture. Based upon the proportions of cells that express CD5 as well as those of the cells surviving in culture, it was calculated that 15–25 % of the total CD5^? B cells were induced to express CD5. Unlike CD5^? B cells, CD5⁺ B cells proliferated vigorously in response to PMA as assessed by [³H] thymidine incorporation and cell cycle analysis in vitro. However, the expression of CD5 by CD5^? B cells was not related to the selective expansion of some CD5⁺ B cells left over as contaminant cells since this occurred in the absence of cell proliferation. Upon exposure to PMA, CD5^? B cells remained in the G0-G1 phases of the cell cycle and did not express the Ki67 antigen or incorporate [³H] thymidine. Furthermore, mitomycin C treatment of the CD5^? B cells did not prevent CD5 expression. Phenotypic studies disclosed that CD5⁺ B cells but not CD5^? B cells expressed CD39. This finding offered the opportunity to carry out an additional control experiment. Separation of the two populations according to the expression of CD39 confirmed the finding obtained by fractionating the cells into CD5⁺ and CD5^? B cells. The cells induced to express CD5 also expressed CD38 that was not detected on resting CD5^? B cells. In this respect, the CD5^? B cells that converted into CD5⁺ cells (inducible CD5⁺ B cells) resembled the cells from the CD5⁺ B cell fractions that up-regulated CD5 and also expressed CD38 upon exposure to PMA alone. Another example of coordinate expression of these two antigens was the finding that exposure to PMA in the presence of recombinant interleukin-4 (rIL-4) resulted in inhibition of the expression of CD5 and CD38. Although virtually all of the tonsillar CD5^? B cells expressed the CD69 activation marker, no cells other than those co-expressing CD5 and CD38 were induced to express CD5 by PMA alone. Resting CD5^? B cells failed to express CD5 and/or CD38 when cultured with PMA in the presence of EL4 T cells and IL-4-free T cell supernatants. Although this combination of stimuli induced a vigorous cell proliferation, the failure to express CD5 and CD38 was not related to cell cycling, since mitomicyn C-treated CD5^? B cells also failed to express CD5 or CD38 when exposed to PMA in the presence of EL4 cells with or without T cell supernatants. Thus, exposure to T cells alone was sufficient to down-regulate CD5 and CD38 expression. Collectively, the above findings indicate that mature CD5^? B cells can follow distinct pathways of differentiation depending upon the nature of the stimuli encountered, and that CD5 expression may identify a special B cell subset or a particular stage of B cell differentiation.     

Somatic hypermutation occurs in B cells of terminal deoxynucleotidyl transferase-, CD23-, interleukin-4-, IgD- and CD30-deficient mouse mutants

We show through sequence analysis of rearranged immunoglobulin variable (Ig-V) region genes from memory B cells of mouse mutants generated by gene targeting that terminal deoxynucleotidyl transferase, CD23, interleukin-4, IgD and CD30 are dispensable for somatic hypermutation.     

Anti-CD5 extends the proliferative response of human CD5+ B cells activated with anti-IgM and interleukin-2

The CD5 T cell glycoprotein which is expressed by a subset of B cells has been shown to be involved in T cell activation and proliferation. No similar studies, to date, have addressed the role of CD5 on the B cell subset. CD5⁺ and CD5^? B cells were sorted and stimulated with anti-CD5 monoclonal antibody (mAb) in vitro. The activation and proliferative responses of these two populations, as measured by analysis of proliferation marker, did not differ following anti-μ and interleukin (IL)-2 stimulation. The addition of anti-CD5 did not change the responsiveness of such activated CD5⁺ B cells but resulted in a decrease in CD25 expression. Pre-activation of B cells with phorbol 12-myristate 13-acetate, which increased CD5 expression, failed to alter the proliferative response of CD5⁺ B cells to anti-μ and IL-2 with or without addition of anti-CD5 mAb. Anti-μ and IL-2 treatment of CD5⁺ cells resulted in optimal proliferation measured at day 3 which decreased by day 6. However, addition of anti-CD5 mAb at day 3 prevented this decline in proliferative response. This dose-dependent effect was observed only when the anti-CD5 mAb was presented to the B cells in cross-linked form. Co-stimulation of CD5 did not lower the threshold of antigen to which the B cells responded. Taken together, these data support a functional role for CD5 on B cells acting as an accessory signal, following their primary activation through the B cell receptor complex and highlight differences in the role of CD5 associated with the T cell receptor complex.     

IL-10 is predominantly produced by CD19(low)CD5(+) regulatory B cell subpopulation: characterisation of CD19 (high) and CD19(low) subpopulations of CD5(+) B cells

IL-10 production by CD19(+)CD5(+) B cells was investigated, by determining the expression levels of CD19, a classical B cell marker. Peripheral mononuclear cells were stained with fluorescence-conjugated anti-CD5, anti-CD19, anti-IL-10, and Annexin V. Interestingly, IL-10-producing B cells were found to be localised within the CD19(low)CD5(+) B cell subset. Apoptotic changes were also observed mainly in CD19(low) cells among B cells. Thus, CD5(+) B cells should be classified as CD19(high) and CD19(low) cells, and the immunological significance of CD19 for the IL-10 production by CD5(+) B cells requires further studies.     

CD5+ B cells and naturally occurring autoantibodies in cancer patients.

We have determined the percentage of CD5+ B lymphocytes in the peripheral blood of cancer patients and healthy controls, using antibodies directed at the CD5 and CD19 (pan-B) markers. The frequencies of CD5+ B cells, expressed as a percentage of total B cells, ranged from 14.3 to 57.5% in the controls and from 14.8 to 82.8% in the patient population. One-third of the cancer patients had frequencies greater than 2 s.d. above the mean of the control population. The CD5+ B cell fraction expressed as a percentage of total lymphocytes was also significantly elevated in this group of cancer patients. These results suggest that the CD5+ B cell compartment may be affected by the malignant process or by the therapy modality employed. The plasma levels of several naturally occurring autoantibodies, the products of the CD5+ B cells, were also assessed in cancer patients and controls. No significant differences were observed when reactivity to several autoantigens was measured. These included nuclear components and phospholipids.     

重症肌无力患者CD5+B细胞的变化

目的：研究ＣＤ＾＋Ｂ细胞在重症肌无力（ＭＣ）发病中的作用。方法Ｌ：采用免疫荧光双标记技术和流式细胞仪对３９例ＭＧ患者和１８例健康对照者周围血中ＣＤ５＾＋细胞（ＣＤ５＾＋ＣＤ１９＾＋）的百分率进行测定,同时用ＥＬＩＳＡ间接法检测ＭＣ患者血清中ＡｃｈＲａｂ。结果：在ＭＧ患者周围血ＣＤ５＾＋Ｂ细胞百分率显著高于对照组,而且在血清ＡｃｈＲａｂ阳性和阴性ＭＧ中ＣＤ５＾＋Ｂ细胞均明显高于对照组;但在血清Ａｃｈ     

Repertoire of CD5+ and CD5- cord blood B cells: specificity and expression of VH I and VH III associated idiotopes.

Epstein-Barr (EBV)-immortalized B cell clones were established from CD5+ and CD5- cord blood B cells separated by flow cytometry. We have previously shown that IgM from many of the clones was polyreactive, exhibiting reactivity with a number of autoantigens. In this study, IgM produced by the clones was analysed by MoAb for the expression of cross-reactive idiotypes (CRI) associated with rheumatoid factor paraproteins and from defined VH and V kappa subgroups of immunoglobulin heavy and light chains. IgM produced by clones established from CD5+ and CD5- B cells expressed the VH I associated idiotope G8. Furthermore, IgM produced by both sets of clones exhibited a similar frequency of VH III heavy chain subgroup expression, as determined by reactivity with staphylococcal protein A (SpA) and VH III-associated CRI expression (B6 and/or D12). In contrast, expression of the V kappa III-associated 17.109 CRI was significantly higher in IgM antibodies produced by clones established from CD5+ compared with the CD5- clones (32 versus 5%: P less than 0.05). Analysis of the VH and VL subgroup expression by IgM produced by the CD5+ and CD5- cord blood clones, and their autoantigen reactivity profile did not reveal restriction or selection within CD5+ and CD5- populations. However, our data suggest that differences may exist in the expression of certain germ-line genes between CD5+ and CD5- cord blood B cells and might indicate an expansion of CD5+ B cells within the fetal environment.     

Serial study of CD5+ and CD5- B cell subpopulations in 335 HIV seropositive patients.

B cell subpopulations, as defined by double-labelling techniques with CD5 and CD19 monoclonal antibodies (MoAbs), were serially studied in 335 HIV-1 seropositive patients. At the time of the first consultation, no important modifications in either CD5+ or CD5- subpopulations were observed, whatever the stage of the disease. However, in 18 out of the 335 patients (5.37%), a sharp increase in B cells exceeding 20% and 300/mm3 was observed. This increase in B cells was mainly accounted for CD5-CD19+ B cell subpopulations and was associated with: (i) evolution of the disease, since only four patients presented it at their first consultation (one lymphadenopathy-associated syndrome (LAS) and three AIDS); (ii) advanced stages of disease since, at the time of B cell augmentation, two patients were staged as LAS, four as ARC and 12 as AIDS; (iii) a high incidence of non-Hodgkin's lymphomas (NHL) since three out of the 18 patients presented a histologically confirmed NHL and three others a clinical pattern compatible with this diagnosis. However, in three patients with B hyperlymphocytosis, polymerase chain reaction (PCR) studies of immunoglobulin gene rearrangement revealed the existence of a polyclonal expansion of B cells. These results justify inclusion of a pan-B cell marker in routine phenotypic studies of HIV-infected individuals, as well as the search for NHL among patients presenting this abnormality.     

胸腺基质细胞支持下骨髓CD34~+细胞向T细胞体外定向分化

目的：研究人骨髓CD34^＋细胞体外向T细胞定向分化的方法，为研究造血细胞淋系造血活性及T细胞发育和分化提供技术平台。方法：免疫磁珠法分离骨髓CD34^＋细胞，在骨髓基质细胞条件培养液构建的微环境下，在胸腺基质细胞的支持下，使其体外向T细胞定向分化，收集培养的非贴壁细胞，免疫荧光染色后经流式细胞术检测培养不同时间CD1^-CD3^＋细胞、CD3^＋CD4^＋CD8^-细胞及CD3^＋CD4^-CD8^＋细胞比例。结果：培养1周时，培养细胞中以不成熟的CD1^＋CD3^-细胞、CD1^＋CD3^＋细胞为主，可检测到少量CD1^-CD3^＋细胞，随培养时间延长，不成熟细胞比例逐渐减少，而成熟的CD1^-CD3^＋细胞比例逐渐增加；在CD3^＋细胞中，培养初期以不成熟的双阳性细胞CD4^＋CD8^＋为主，而成熟的单阳性CD^＋CD8^-细胞及CD4^-CD8^＋细胞占极小比例，随培养时间延长，双阳性细胞比例逐渐减少，而成熟的单阳性细胞比例逐渐增高；而无胸腺基质细胞支持的CD34＋细胞仅在培养初期检测到成熟细胞存在，而培养后4周基本检测不到成熟T细胞的存在。结论：在骨髓基质细胞及胸腺基质细胞的支持下，骨髓CD34^＋细胞可体外发育为成熟的CD1^-CD3^＋细胞及单阳性T细胞，其中胸腺基质细胞的支持对于造血细胞向T细胞的体外定向分化极其重要。     

CD73对骨髓间充质干细胞增殖与衰老的影响

目的探讨CD73对骨髓间充质干细胞(BMSCs)增殖与衰老的影响。方法培养小鼠BMSCs,构建慢病毒CD73过表达载体和CD73 RNAi干扰载体,分别转染BMSCs,实验分组:CD73过表达组(OE组)、CD73RNAi干扰组(RNAi组)和对照组(CON组)。衰老相关β-半乳糖苷酶(SA-β-Gal)染色检测细胞的衰老情况;MTT法检测细胞增殖能力变化;流式细胞术检测细胞周期变化;透射电子显微镜观测转染后细胞的超微结构;非损伤细胞功能分析仪检测细胞生长曲线。结果慢病毒转染BMSCs后72 h和168 h,衰老细胞数量RNAi组CON组OE组(P0.05);转染后3~4d BMSCs的增殖能力为OE组较RNAi组和CON组细胞增殖速度快(P0.05);转染后3d各组细胞周期的变化是:OE组、RNAi组和CON组的G1期细胞所占比例分别为25.9%、44.1%和51.7%;S期细胞所占比例分别为48.8%、30.9%和26.9%;G2期细胞所占比例分别为25.2%、25.0%和21.4%;透射电子显微镜观察结果显示,OE组细胞质内粗面内质网和核糖体增多;细胞生长曲线显示OE组高于CON组和RNAi组。结论 CD73促进BMSCs增殖且抑制BMSCs衰老。     

CD8+ T cells drive autoimmune hematopoietic stem cell dysfunction and bone marrow failure

Bone marrow (BM) failure syndrome encompasses a group of disorders characterized by BM stem cell dysfunction, resulting in varying degrees of hypoplasia and blood pancytopenia, and in many patients is autoimmune and inflammatory in nature. The important role of T helper 1 (Th1) polarized CD4⁺ T cells in driving BM failure has been clearly established in several models. However, animal model data demonstrating a functional role for CD8⁺ T cells in BM dysfunction is largely lacking and our objective was to test the hypothesis that CD8⁺ T cells play a non-redundant role in driving BM failure. Clinical evidence implicates a detrimental role for CD8⁺ T cells in BM failure and a beneficial role for Foxp3⁺ regulatory T cells (Tregs) in maintaining immune tolerance in the BM. We demonstrate that IL-2-deficient mice, which have a deficit in functional Tregs, develop spontaneous BM failure. Furthermore, we demonstrate a critical role for CD8⁺ T cells in the development of BM failure, which is dependent on the cytokine, IFNγ. CD8⁺ T cells promote hematopoietic stem cell dysfunction and depletion of myeloid lineage progenitor cells, resulting in anemia. Adoptive transfer experiments demonstrate that CD8⁺ T cells dramatically expedite disease progression and promote CD4⁺ T cell accumulation in the BM. Thus, BM dysregulation in IL-2-deficient mice is mediated by a Th1 and IFNγ-producing CD8⁺ T cell (Tc1) response.     

骨髓间充质干细胞对骨髓CD34~+细胞增殖影响的体外研究

研究骨髓间充质干细胞(bone marrow mesenchymal stem cell,BMMSC)对骨髓CD34+细胞增殖的影响,为骨髓CD34+细胞体外扩增的深入研究提供依据。用MACS进行骨髓CD34+细胞的分选;用流式细胞术进行CD34+细胞纯度鉴定;用密度梯度离心法分离引产胎儿骨髓单个核细胞,结合贴壁法进行BMMSC的体外扩增培养;用流式细胞术进行BMMSC表面标志鉴定;用Transwell培养板培养CD34+细胞与BMMSC;用自动细胞计数仪计数有活性的CD34+细胞数量;用MTT比色法检测骨髓CD34+细胞增殖活性。流式细胞术检测结果显示分选所得的CD34+细胞纯度达到90%以上;流式细胞术检测显示传至第3代继续培养72h后的BMMSC高表达CD44、CD29,而HLA-DR、CD45、CD34表达阴性,说明所培养的BMMSC纯度很高;Transwell培养板培养CD34+细胞与BMMSC,在倒置显微镜下观察以及自动细胞计数仪计数发现,实验组有活性的CD34+细胞数量高于对照组(P<0.05);采用MTT比色法检测骨髓CD34+细胞的增殖活性,实验组高于对照组(P<0.05)。以上结果说明BMMSC有促进骨髓CD34+细胞增殖的作用,这种作用可能与其分泌的细胞因子有关。